Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

Name: Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Published: 2019
License: Public Domain

Merck Sharp & Dohme LLC · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

carcinoma

carcinoma, squamous cell, programmed cell death-1 (pd-1), programmed cell death 1, pd1, programmed cell death ligand 1 (pd-l1), programmed cell death ligand 2 (pd-l2), pdl1, pdl2, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

Related documents